FDA Floats OTC Monograph Overhaul To Be “More Agile And Responsive”
This article was originally published in The Tan Sheet
Executive Summary
The agency will conduct a public hearing March 25-26 for comments about improving the OTC monograph process, which currently faces “significant challenges.” FDA’s proposals include expanding the process for allowing deviations from formulations approved through NDAs and issuing monographs by administrative order.
You may also be interested in...
Gottlieb An Anchor For OTC Drug Industry On Stormy Congressional Seas
Commissioner Gottlieb has been a “very strong champion” of FDA and his interest in improving the OTC monograph and switch processes provides hope to the industry during a tumultuous legislative era, say CHPA executives at their annual meeting in Florida. They expect monograph reform will happen this year but doubt much else will happen before mid-term elections in November.
Gottlieb An Anchor For OTC Drug Industry On Stormy Congressional Seas
Commissioner Gottlieb has been a “very strong champion” of FDA and his interest in improving the OTC monograph and switch processes provides hope to the industry during a tumultuous legislative era, say CHPA executives at their annual meeting in Florida. They expect monograph reform will happen this year but doubt much else will happen before mid-term elections in November.
Codeine Concerns Cough Up FDA's OTC Monograph Problems
Pew Charitable Trusts joins CHPA, medical groups in urging Congress to authorize moving the US monograph system to an administrative process and to authorize a monograph user fee program.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: